Skip to main content

Table 2 Baseline demographic and clinical characteristics

From: Effects of concomitant use of prasugrel with edoxaban on bleeding time, pharmacodynamics, and pharmacokinetics of edoxaban in healthy elderly Japanese male subjects: a clinical pharmacology study

 All subjectsGroup 1
30 mg edoxaban plus 2.5 mg prasugrel
Group 2
30 mg edoxaban plus 3.75 mg prasugrel
n = 24n = 12n = 12
Age (years)
 Mean (SD)72 (4)71 (4)73 (3)
 65 to < 75, n (%)16 (66.7)9 (75.0)7 (58.3)
 75 to 80, n (%)8 (33.3)3 (25.0)5 (41.7)
Height (cm)
 Mean (SD)164.0 (5.7)162.5 (5.7)165.5 (5.6)
Weight (kg)
 Mean (SD)56.4 (2.2)55.8 (2.4)57.0 (1.9)
 > 50 to 60, n (%)24 (100.0)12 (100.0)12 (100.0)
BMI (kg/m2)
 Mean (SD)21.1 (1.6)21.3 (1.6)21.0 (1.6)
eGFR (mL/min/1.73m2)
 Mean (SD)73.5 (7.0)75.5 (6.6)71.6 (7.1)
 60 to < 90, n (%)24 (100.0)12 (100.0)12 (100.0)
CLcr(mL/min)
 Mean (SD)67.2 (7.2)68.7 (6.1)65.8 (8.1)
 ≥50, n (%)24 (100.0)12 (100.0)12 (100.0)
Medical historya
 No, n (%)10 (41.7)5 (41.7)5 (41.7)
 Yes, n (%)14 (58.3)7 (58.3)7 (58.3)
  1. SD standard deviation, IQR interquartile range, BMI body mass index, CLcr creatinine clearance
  2. aAppendicitis, polyps in the colon, hemorrhoids, cataract, hepatitis A, tuberculosis, and inguinal hernia